Front. Cell Dev. Biol. Frontiers in Cell and Developmental Biology Front. Cell Dev. Biol. 2296-634X Frontiers Media S.A. 1728870 10.3389/fcell.2025.1728870 Correction Correction: Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma Yun et al. 10.3389/fcell.2025.1728870 Yun Wuyang 1 Writing - original draft Writing - review and editing Li Yuyu 2 † Ge Yanlei 3 † Zhang Xiaoyun 1 Liu Huifeng 4 * Chen Wen 2 * Xiao Li 5 * Hebei North University, Zhangjiakou, China Department of Pathology, The 8th Medical Center of PLA General Hospital, Beijing, China North China University of Science and Technology Affiliated Hospital, Tangshan, China Department of Respiratory and Critical Care Medicine, The 8th Medical Center of PLA General Hospital, Beijing, China College of Pulmonary and Critical Care Medicine, Beijing Key Laboratory of Organ Transplantation and Immunology Regulatory, The 8th Medical Centre of Chinese PLA General Hospital, Beijing, China Correspondence: Huifeng Liu, liuhf309@sina.com; Wen Chen, dr.chen20160224@foxmail.com; Li Xiao, xiaolilab309@163.com

These authors have contributed equally to this work

 24 11 2025 2025 13 1728870 21 10 2025 20 10 2025 14 11 2025 Copyright © 2025 Yun, Li, Ge, Zhang, Liu, Chen and Xiao. 2025 Yun, Li, Ge, Zhang, Liu, Chen and Xiao https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma by Yun W, Li Y, Ge Y, Zhang X, Liu H, Chen W and Xiao L (2025). Front. Cell Dev. Biol. 13:1639922. doi: 10.3389/fcell.2025.1639922 lung cancer organoid model chemotherapy response resistance evolution Clinical Prediction precision oncology section-in-acceptance Cancer Cell Biology

There was a mistake in Figure 1C as published.

The Organoid Model Demonstrates Advantages in Simulating 3D Spatial Structure and Morpho Function. (A) Phase-contrast microscopy images show that the organoid diameter increased with culture time, reaching 100–200 µm by day 7 (20×, scale bar: 100 µm). (B) Representative HE and immunohistochemical CK7 staining for the organoid model, animal model, and adherent model. The organoid model preserved the adenomatous structure of lung adenocarcinoma and exhibited strong CK7 expression (20×, scale bar: 100 µm). (C) Growth cycles of models based on the A549 cell line. The organoid model completed functional construction within 9 days.

Panel A shows cell cultures over three days, with visible growth and structural changes. Panel B presents three histological models: Organoid, Animal, and Adherent, each stained with Hematoxylin and Eosin (HE) and marked for Cytokeratin (CK). Panel C is a diagram illustrating the timeline from initial cell model to Adherent Model (two to three days), Organoid Model (seven to nine days), and Animal Model (two to three weeks).

In Figure 1C the culture time for the adherent model was incorrectly stated as 2–3 weeks. The correct cultivation time for the adhesive model should be 2–3 days. The corrected Figure 1 appears below.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Yahima Frión-Herrera, University of Padua, Italy